TY - JOUR
T1 - Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy
AU - Parodi, Maurizio Battaglia
AU - Iacono, Pierluigi
AU - Cascavilla, Marialucia
AU - Zucchiatti, Ilaria
AU - Kontadakis, Dimitrios Stylianos
AU - Bandello, Francesco
PY - 2010/9
Y1 - 2010/9
N2 - PURPOSE. To assess the effects of intravitreal bevacizumab injections in the treatment of subfoveal choroidal neovascularization (CNV) associated with pattern dystrophy (PD) of the retinal pigment epithelium. METHODS. The study was a prospective, nonrandomized, openlabel, interventional clinical trial in which 12 patients were prospectively enrolled. Patients with a diagnosis of PD complicated by subfoveal CNV were considered for the study. All patients underwent a complete ophthalmic examination, including ETDRS visual acuity measurement, electroretinogram, electrooculogram, optical coherence tomography, and fluorescein angiography. The treatment protocol began with a loading dose of three consecutive injections at 1-month intervals, followed by injections administered as needed, according to OCT parameters and angiographic features observed during a 24-month follow-up period. The number of eyes with a visual acuity loss of fewer than 15 letters (
AB - PURPOSE. To assess the effects of intravitreal bevacizumab injections in the treatment of subfoveal choroidal neovascularization (CNV) associated with pattern dystrophy (PD) of the retinal pigment epithelium. METHODS. The study was a prospective, nonrandomized, openlabel, interventional clinical trial in which 12 patients were prospectively enrolled. Patients with a diagnosis of PD complicated by subfoveal CNV were considered for the study. All patients underwent a complete ophthalmic examination, including ETDRS visual acuity measurement, electroretinogram, electrooculogram, optical coherence tomography, and fluorescein angiography. The treatment protocol began with a loading dose of three consecutive injections at 1-month intervals, followed by injections administered as needed, according to OCT parameters and angiographic features observed during a 24-month follow-up period. The number of eyes with a visual acuity loss of fewer than 15 letters (
UR - http://www.scopus.com/inward/record.url?scp=77957354664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957354664&partnerID=8YFLogxK
U2 - 10.1167/iovs.10-5237
DO - 10.1167/iovs.10-5237
M3 - Article
C2 - 20375343
AN - SCOPUS:77957354664
VL - 51
SP - 4358
EP - 4361
JO - Investigative Ophthalmology and Visual Science
JF - Investigative Ophthalmology and Visual Science
SN - 0146-0404
IS - 9
ER -